$117.30 -$6.64 (0.0%)

03:38 PM EDT on 06/14/19

Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 5 out of 5

Current Price $117.30 Mkt Cap $6.8B
Open $123.61 P/E Ratio 0.00
Prev. Close $117.30 Div. (Yield) $0.00 (0.0%)
Daily Range $115.90 - $123.61 Volume 169,439
52-Wk Range $95.79 - $163.33 Avg. Daily Vol. 10

Caps

How do you think NASDAQ:BLUE will perform against the market?

Add Stock to CAPS Watchlist

All Players

269 Outperform
16 Underperform
 

All-Star Players

93 Outperform
3 Underperform
 

Wall Street

6 Outperform
0 Underperform
 

Top NASDAQ:BLUE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

SaintCroix (99.36)
Submitted February 14, 2018

I am very impressed with Nick Leschly. You can watch his Ted Talk here:https://www.youtube.com/watch?v=Ez560GnkSrE

TMFFlygal (99.44)
Submitted December 08, 2015

Selling for a while after the huge drop today, good for a trade

NASDAQ:BLUE VS S&P 500 (SPY)

Fools bullish on NASDAQ:BLUE are also bullish on:

Fools bearish on NASDAQ:BLUE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BLUE.

Recs

0
Member Avatar MarkFitzFool (40.95) Submitted: 5/11/2019 12:39:01 PM : Outperform Start Price: $132.45 NASDAQ:BLUE Score: -14.08

$BLUE is a leader in the new wave, the future, of personalized genomic therapies based on both gene editing and immunotherapy. They're ahead of Edits when it comes to bringing their Beta-Thalassemia and Sickle Cell Disease therapies to market. Mark my words, they will be the first to market with those therapies (although there is room for several players in the space). They have impressive partnerships with Regeneron, Celgene, Boston Children's Hospital, Seattle Children's Hospital, etc. I know from speaking to some senior scientists at the company, that they plan to file FDA approval for at least four candidate therapies within the next two years. Beta-Thalassemia approval in the EU will likely come first. Is it a risky investment? Yes, a bit, as is the nature of virtually all developmental and pre-clinical stage biotechs, but they are a true leader, and I don't see them going away or failing anytime soon.

Recs

0
Member Avatar TMFang4apples (51.15) Submitted: 4/24/2019 9:36:31 PM : Outperform Start Price: $141.88 NASDAQ:BLUE Score: -16.08

The future for CAR-T and complex therapies with long hospital stays looks much better.

Recs

0
Member Avatar shanelofgren (31.48) Submitted: 1/2/2019 12:56:29 PM : Outperform Start Price: $99.28 NASDAQ:BLUE Score: +2.28

Renewing pick. Bullish bet on their CAR-T capabilities and manufacturing investments.

Leaderboard

Find the members with the highest scoring picks in BLUE.

Score Leader

DoubleBagel

DoubleBagel (33.82) Score: +669.10

The Score Leader is the player with the highest score across all their picks in BLUE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille12 30.30 4/16/2014 Outperform 5Y $19.11 +513.81% +56.10% +457.72 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.63 11/5/2013 Outperform 5Y $20.53 +471.36% +64.68% +406.68 0 Comment
portefeuille2 98.67 4/11/2014 Outperform 5Y $20.74 +465.57% +59.36% +406.22 0 Comment
portefeuille3 96.78 4/11/2014 Outperform 5Y $20.74 +465.57% +59.49% +406.09 0 Comment
portefeuille6 99.47 4/11/2014 Outperform 5Y $20.91 +460.98% +59.70% +401.28 0 Comment
johninmadison 87.85 4/7/2014 Outperform 5Y $21.07 +456.72% +55.93% +400.79 0 Comment
HoosierDoozer < 20 2/5/2014 Outperform 5Y $20.84 +462.86% +65.84% +397.02 0 Comment
portefeuille 98.21 4/8/2014 Outperform 5Y $21.44 +447.11% +57.25% +389.86 1 Comment
jack0071 70.73 1/8/2014 Outperform 5Y $21.47 +446.34% +58.01% +388.33 0 Comment
jtothes 76.80 2/14/2014 Outperform 3Y $21.88 +436.11% +58.54% +377.57 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackEvercorePar 82.88 6/19/2018 Outperform NS $179.40 -34.62% +5.79% -40.41 0 Comment
TrackBMOCapital < 20 6/6/2017 Outperform NS $95.43 +22.92% +19.12% +3.80 0 Comment
Anonymous331 34.88 5/30/2017 Outperform 5Y $78.60 +39.82% +0.31% +39.51 6/16/2017 @ $109.90 0 Comment
TrackJimCramer 86.18 5/27/2015 Outperform 3W $189.69 -38.16% +36.28% -74.44 0 Comment
TrackJimCramer 86.18 3/13/2015 Underperform 3W $119.93 +58.17% +3.34% -54.83 5/27/2015 @ $189.69 0 Comment
TrackPiperJaff 86.10 12/9/2014 Outperform NS $77.42 +51.51% +41.84% +9.68 0 Comment
TrackRothCapital 69.39 9/22/2014 Outperform NS $36.70 +219.62% +44.68% +174.94 0 Comment
TrackJimCramer 86.18 3/20/2014 Outperform 3W $26.83 +347.00% +9.63% +337.37 3/13/2015 @ $119.93 0 Comment
TrackWedbush 88.21 7/15/2013 Outperform NS $32.37 +262.37% +72.57% +189.80 0 Comment

Advertisement